Tag Archives: Maprotiline

Pharmacological Treatment of Pain

While medications are often prescribed for all types of chronic pain, research has consistently shown that several classes have proven efficacy for the treatment of neuropathic pain. Ideally, pharmacotherapy of pain would be specifically selected on the basis of considerations of etiology (e.g., ischemic, neuropathic), pathophysiology (e.g., demyelination, central pain), and anatomy (e.g., C fibers,… Read More »

Minor Depression: Escitalopram, Paroxetine, Sertraline, and Fluoxetine

Selective Serotonin Reuptake Inhibitors The seven available agents in the selective serotonin reuptake inhibitor class are citalopram (Lund-beck’s Cipramil, Forest Laboratories’ Celexa, generics) and its single enan-tiomer, escitalopram (Lundbeck’s Cipralex, Forest’s Lexapro); paroxetine (GSK’s Paxil/Seroxat, Novartis’s Frosinor, generics); the controlled-release version of paroxetine (GSK’s Paxil CR); sertraline (Pfizer’s Zoloft); fluoxetine (Eli Lilly’s Prozac, generics); and… Read More »

Drug treatment of elderly patients with depression

There is a consensus that antidepressant therapy is effective and should be recommended for the treatment of depression in the elderly. Because of the pharmacokinetic changes in the elderly, the tolerability of antidepressants, especially of the classic tricyclics, is reduced compared with younger populations. However, this problem can be managed by a careful dosing regime… Read More »

Personality and Response to Antidepressant Medication

Personality Disorders Although the general consensus among clinicians is that patients who present with comorbid depression and personality disorders have a worse outcome, this is not always supported by research findings. Several large clinical investigations did find evidence to support an adverse outcome in depressed patients with comorbid personality disorders. In a study designed to… Read More »

Major Depressive Disorder And Alzheimer’s Disease

Prevalence Major depressive disorders in Alzheimer’s disease are less common than depressive symptoms, although most studies have described increased rates compared to the general population. Published prevalence rates have a very large range, presumably because of sampling issues (clinical, convenience and population samples) as well as differing diagnostic schema. Because of this lack of consistency… Read More »

Pharmacotherapy of Treatment of Depression in Late Life

Antidepressant pharmacotherapy has become the cornerstone of management of depression in late life. Evidence from a number of meta-analyses documents convincingly that antidepressant medications are effective treatments of late-life depression. The newer medications were found to be as effective as tricyclic antidepressants () in these analyses, and generally are associated with fewer discontinuations due to… Read More »

Premenstrual Dysphoric Disorder

Prevalence The diagnosis of premenstrual dysphoric disorder (premenstrual dysphoric disorder) according to DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision) requires five or more symptoms, for most of a 12-month time span, which start after ovulation and disappear shortly after the onset of menses (Table Symptoms of premenstrual dysphoric disorder). They… Read More »

Pharmacotherapeutic Treatments for Panic Disorder

Selective Serotonin Reuptake Inhibitors The selective serotonin reuptake inhibitors have become the mainstay of pharmacological treatment for mood and anxiety disorders. Selective serotonin reuptake inhibitors were considered the first-line treatment by a group of experts in anxiety for years before controlled studies appeared, and a meta-analysis of the controlled studies up to 1995 that included… Read More »

Pharmacotherapy for Generalized Anxiety Disorder

In this site, we focus on pharmacotherapy for generalized anxiety disorder. For much of recorded history, chronic anxiety has been treated with pharmacological agents. Starting with alcohol in prehistoric times and extending through the nineteenth century with the use of bromides, chloral hydrate, and paraldehyde and into the twentieth century with the synthesis of barbiturates,… Read More »

Matching SSRI to Depressive Subtype

Atypical Depression Atypical depression is characterized by mood reactivity and two of the following: weight or appetite increase, hypersomnia, leaden paralysis and a pattern of interpersonal rejection sensitivity. MAOIs have been found to be superior to TCAs for atypical depression but recent views are that SSRIs are also an effective treatment for this subtype. Response… Read More »